Clovis intends to offer, subject to market and other conditions, USD 200m aggregate principal amount of its convertible senior notes due 2025 in an underwritten registered public offering.
In connection with this offering, Clovis intends to grant the underwriters a 30-day option to purchase up to an additional USD 30m aggregate principal amount of the convertible senior notes on the same terms and conditions.
The holders of the notes may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date, May 1, 2025. The interest rate, conversion rate and other terms of the notes will be determined at the time of pricing of the offering of the notes.
Clovis also intends to offer concurrently, subject to market and other conditions, USD100 m of shares of its common stock in an underwritten registered public offering.
In connection with this offering, Clovis intends to grant to the underwriters a 30-day option to purchase up to an additional USD 15m of shares of its common stock on the same terms and conditions.
All shares of the common stock to be sold in the offering will be offered by Clovis Oncology.
Clovis Oncology intends to use the combined net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca (rucaparib) in the US and, if approved by the European Commission in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates, or businesses and working capital.
Clovis Oncology focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally. The company is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories